Siegel R.L. .2017 .A Cancer Journal for Clinicians. , 67 : 7-30.
Boire A. .2004 .PAR1 Is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. ” Cell, 12 : 303-313.
Carlson R.W. .2012 .Featured Updates to the NCCN Guidelines. ” Journal of the National Comprehensive Cancer Network, 10 : 821-829.
Beeghly-Fadiel A. .2009 .No association between matrix metalloproteinase-1 or matrix metalloproteinase-3 polymorphisms and breast cancer susceptibility. Biomarkers & Prevention, 09 : 1055-9965.
Slattery M.L. .2013 .Matrix Metalloproteinase Genes Are Associated with Breast Cancer Risk and Survival. ” PLOS One, 8 : .
Tower G.B. .2003 .The 2G Single Nucleotide Polymorphism in the MMP-1 Promoter Contributes to High Levels of MMP1 Transcription.” Breast Cancer Research and Treatment. , 0000003948 : 75-82.
Zhou J. .2011 .. Analysis of Matrix Metalloproteinase-1 Gene Polymorphisms and Expression in Breast Tumors.” Cancer Investigation, 29 : 599-607.
Amin M. . .A Cancer Journal for Clinicians. , 67(2017) : 93-99.
Pallant J. SPSS Survival,Manual J. SPSS Survival .2020 .. , : .
Jezequel P. .2012 .bc-GenExMiner: An Easy-to-Use Online Platform for Gene Prognostic Analyses. Breast Cancer Research and Treatment, 131 : 765-775.
Jezequel P. .2013 .. bc-GenExMiner 3, : .
Genome Atlas Network Cancer .2012 .. Comprehensive Molecular Portraits of Human Breast Tumours.” Nature, 490 : 61-70.
Gao J. .2013 .. Integrative Analysis of Complex Cancer Genomics Using cBioPortal.” Science Signaling, 6 : .
Cerami E. . .. The cBio Cancer Genomics Portal.” Cancer Discovery, 12(2012) : 2159-8290.
Visse R.,Nagase R.,Inhibitors Tissue .2003 .Matrix Metalloproteinases. Circulation Research, 0000070112(8) : 827-839.
Xuan J. .2015 .. Matrix Metalloproteinase-1 Expression in Breast Cancer.” Biomedical Reports, 3(3) : 395-397.
McGranahan N.,Swanton C.,Evolution Tumor .2017 .. Cell, 01 : 613-628.
Savas P. .2015 .Clinical Relevance of Host Immunity in Breast Cancer. Nature Reviews Clinical Oncology, 13 : 228-241.
Waks A.G.,Winer E.P. .2018 .Breast cancer treatment: A review. ” JAMA, 321 : 288-300.
Harbeck N.,Gnant M. .2017 .Breast cancer. The Lancet, 6736(16) : 31891-8.
Wu X. .2024 .Prognostic significance of ER-to-PR difference. ” Scientific Reports, 14 : .
Zhou Z. .2018 .. polymorphism and cancer Risk.” Disease Markers, : MMP1.
Decock J. .2011 .Matrix metalloproteinases: Protective roles in cancer. ” Journal of Cellular and Molecular Medicine, 01302 : 4934-1265.
Cui N. .2017 .Biochemical and biological attributes of matrix metalloproteinases. ” Progress in Molecular Biology and Translational Science, 02 : 1-73.
Gyorffy B. .2010 .Online survival analysis tool. Breast Cancer Research and Treatment, 123 : 725-731.
Tsang J.Y.S.,Tse G.M. “ .2020 .Molecular classification of breast cancer. ” Advances in Anatomic Pathology, 27 : 27-35.
Mook S. .2009 .Calibration and accuracy of prognosis calculation. The Lancet Oncology, 09 : 70254-2.
Gialeli C. .2010 .Roles of matrix metalloproteinases in cancer progression. ” FEBS Journal, 07919 : 4658-27.
Denkert C. .2018 .Tumour-Infiltrating lymphocytes and prognosis. The Lancet Oncology, 17 : 30904-50.
Poola I. .2005 .Identification of MMP-1 as a breast cancer marker. ” Nature Medicine, 11(5) : 481-483.
Kousidou O.C.,NovemberDecember O.C. .2004 .Expression of MMPs and TIMPs genes. Anticancer Research, 24(6) : 4025-4030.
Wolff A.C. .2018 .HER2 testing in breast cancer. ” Journal of Clinical Oncology, 77(20) : 2105-2122.
Kurnia I. .2022 .Molecular Patho-mechanisms of Cervical Cancer (. ” Annals of Medicine and Surgery, 77 : .